Cargando…

Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy

Purpose. The impact of critical illness on survival of HIV-infected patients in the era of antiretroviral therapy remains uncertain. We describe the epidemiology of critical illness in this population and identify predictors of mortality. Materials and Methods. Retrospective cohort of HIV-infected p...

Descripción completa

Detalles Bibliográficos
Autores principales: Turvey, Shannon L., Bagshaw, Sean M., Eurich, Dean T., Sligl, Wendy I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350334/
https://www.ncbi.nlm.nih.gov/pubmed/28348607
http://dx.doi.org/10.1155/2017/7868954
_version_ 1782514639698919424
author Turvey, Shannon L.
Bagshaw, Sean M.
Eurich, Dean T.
Sligl, Wendy I.
author_facet Turvey, Shannon L.
Bagshaw, Sean M.
Eurich, Dean T.
Sligl, Wendy I.
author_sort Turvey, Shannon L.
collection PubMed
description Purpose. The impact of critical illness on survival of HIV-infected patients in the era of antiretroviral therapy remains uncertain. We describe the epidemiology of critical illness in this population and identify predictors of mortality. Materials and Methods. Retrospective cohort of HIV-infected patients was admitted to intensive care from 2002 to 2014. Patient sociodemographics, comorbidities, case-mix, illness severity, and 30-day mortality were captured. Multivariable Cox regression analyses were performed to identify predictors of mortality. Results. Of 282 patients, mean age was 44 years (SD 10) and 169 (59%) were male. Median (IQR) CD4 count and plasma viral load (PVL) were 125 cells/mm(3) (30–300) and 28,000 copies/mL (110–270,000). Fifty-five (20%) patients died within 30 days. Factors independently associated with mortality included APACHE II score (adjusted hazard ratio [aHR] 1.12; 95% CI 1.08–1.16; p < 0.001), cirrhosis (aHR 2.30; 95% CI 1.12–4.73; p = 0.024), coronary artery disease (aHR 6.98; 95% CI 2.20–22.13; p = 0.001), and duration of HIV infection (aHR 1.07 per year; 95% CI 1.02–1.13; p = 0.01). CD4 count and PVL were not associated with mortality. Conclusions. Mortality from an episode of critical illness in HIV-infected patients remains high but appears to be driven by acute illness severity and HIV-unrelated comorbid disease rather than degree of immune suppression.
format Online
Article
Text
id pubmed-5350334
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-53503342017-03-27 Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy Turvey, Shannon L. Bagshaw, Sean M. Eurich, Dean T. Sligl, Wendy I. Can J Infect Dis Med Microbiol Research Article Purpose. The impact of critical illness on survival of HIV-infected patients in the era of antiretroviral therapy remains uncertain. We describe the epidemiology of critical illness in this population and identify predictors of mortality. Materials and Methods. Retrospective cohort of HIV-infected patients was admitted to intensive care from 2002 to 2014. Patient sociodemographics, comorbidities, case-mix, illness severity, and 30-day mortality were captured. Multivariable Cox regression analyses were performed to identify predictors of mortality. Results. Of 282 patients, mean age was 44 years (SD 10) and 169 (59%) were male. Median (IQR) CD4 count and plasma viral load (PVL) were 125 cells/mm(3) (30–300) and 28,000 copies/mL (110–270,000). Fifty-five (20%) patients died within 30 days. Factors independently associated with mortality included APACHE II score (adjusted hazard ratio [aHR] 1.12; 95% CI 1.08–1.16; p < 0.001), cirrhosis (aHR 2.30; 95% CI 1.12–4.73; p = 0.024), coronary artery disease (aHR 6.98; 95% CI 2.20–22.13; p = 0.001), and duration of HIV infection (aHR 1.07 per year; 95% CI 1.02–1.13; p = 0.01). CD4 count and PVL were not associated with mortality. Conclusions. Mortality from an episode of critical illness in HIV-infected patients remains high but appears to be driven by acute illness severity and HIV-unrelated comorbid disease rather than degree of immune suppression. Hindawi Publishing Corporation 2017 2017-02-27 /pmc/articles/PMC5350334/ /pubmed/28348607 http://dx.doi.org/10.1155/2017/7868954 Text en Copyright © 2017 Shannon L. Turvey et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Turvey, Shannon L.
Bagshaw, Sean M.
Eurich, Dean T.
Sligl, Wendy I.
Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_full Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_fullStr Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_full_unstemmed Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_short Epidemiology and Outcomes in Critically Ill Patients with Human Immunodeficiency Virus Infection in the Era of Combination Antiretroviral Therapy
title_sort epidemiology and outcomes in critically ill patients with human immunodeficiency virus infection in the era of combination antiretroviral therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350334/
https://www.ncbi.nlm.nih.gov/pubmed/28348607
http://dx.doi.org/10.1155/2017/7868954
work_keys_str_mv AT turveyshannonl epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy
AT bagshawseanm epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy
AT eurichdeant epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy
AT sliglwendyi epidemiologyandoutcomesincriticallyillpatientswithhumanimmunodeficiencyvirusinfectionintheeraofcombinationantiretroviraltherapy